
The IBCC-led PHERGain clinical trial demonstrates that PET-CT can identify patients with localized HER2-positive breast cancer who could be treated without preoperative chemotherapy
Researchers from the International Breast Cancer Center (IBCC) have led the PHERGain clinical trial that shows that PET-CT could identify around 40% of patients with localized